Drugs / AUT00206
last change Apr 2019 re-read 2 minutes ago

AUT00206

Small molecule

Developed for
schizophrenia
Investigated by
Autifony Therapeutics Limited · King's College London · University of Manchester

Trials 3 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03164876 Apr 2017 → Apr 2019 schizophrenia Autifony Therapeutics Limited Completed No outcome recorded
Phase 1 NCT02935725 Oct 2016 → Nov 2017 schizophrenia Autifony Therapeutics Limited Completed No outcome recorded
Phase 1 NCT02589262 Sep 2015 → Jul 2016 schizophrenia Autifony Therapeutics Limited Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as AUT00206 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02589262
2

NCT02935725

NCT03164876

Modality Small molecule CHEMBL5314948
Route Oral “by mouth” NCT02589262